Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public











Title  Creator  Group name  Publishing year 
[Preventing the risks of interaction between cancer treatments and complementary care strategies] Ninot et al. EquipeAD 2024-11-15
Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug-Drug Interactions Are the Usual Suspects Leenhardt et al. EquipeCTCS 2022-04-11
Oral targeted therapy dose adaptation in older patients with cancer: A real-life French cohort Carbasse et al. EquipePM 2022-07
Case report: Liquid biopsy, the sooner the better? Thomas et al. EquipePC 2022
PXR Modulates the Prostate Cancer Cell Response to Afatinib by Regulating the Expression of the Monocarboxylate Transporter SLC16A1 Matheux et al. EquipeCG 2021-07-20
Impact of pharmacist consultation at clinical trial inclusion: an effective way to reduce drug-drug interactions with oral targeted therapy Leenhardt et al. EquipeELC 2021-10
Alpelisib for the treatment of PIK3CA-mutated, hormone receptor-positive, HER2-negative metastatic breast cancer Leenhardt et al. EquipeCTCS 2021-04
Liquid chromatography-tandem mass spectrometric assay for the quantification of CDK4/6 inhibitors in human plasma in a clinical context of drug-drug interaction Leenhardt et al. EquipeCTCS 2020-09-05


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés